Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying disease often progresses, indicating the need for a deeper understanding of its molecular mechanisms.
The Role of Tau Protein in Neurodegenerative Diseases
Tau, a microtubule-associated protein, is central to several neurodegenerative diseases, including Alzheimer’s disease (AD) and various Tauopathies. In these conditions, hyperphosphorylation of Tau disrupts the stability of the neuronal microtubular lattice, leading to the formation of toxic aggregates. While Tau’s role in the brain is well-studied, its involvement in retinal neurodegeneration, particularly in glaucoma, remains less clear.
Investigating Tau in Glaucoma
Prior research has shown changes in Tau expression and phosphorylation in the retina in both AD and glaucoma, but the causative or downstream nature of these changes is unclear. This study aimed to elucidate the impact of Tau protein modulation on retinal neurons under normal and experimental glaucoma conditions.
Methodology
Using AAV9-mediated gene therapy, researchers induced Tau overexpression and knockdown in mouse retinas. Both manipulations negatively affected retinal structure, function, and neuroprotective Akt/Erk signaling under normal conditions. In an experimental glaucoma model, Tau overexpression exacerbated inner retinal degeneration, while Tau silencing significantly protected against these changes.
Key Findings
- Tau Overexpression and Knockdown: Both Tau overexpression and silencing disrupted retinal structural and functional measures under normal IOP conditions, highlighting the necessity of balanced Tau levels for retinal health.
- Impact on Experimental Glaucoma: Tau overexpression worsened inner retinal degeneration in glaucoma, while Tau silencing provided significant protection, underscoring the therapeutic potential of targeting Tau.
- Biochemical Pathways: Tau modulation affected various biochemical pathways, including ER stress markers and the Akt/Erk signaling pathways, crucial for cell survival and neuroprotection.
- Synaptic Integrity: Changes in Tau expression influenced synaptic markers, suggesting Tau’s role in synaptic function and axonal signal transduction in the retina.
Conclusion
This study highlights the critical role of endogenous Tau protein levels in maintaining retinal integrity and provides compelling evidence for targeting Tau in glaucoma therapy. By elucidating the molecular mechanisms underlying Tau’s involvement in retinal degeneration, these findings pave the way for developing novel therapeutic strategies aimed at modulating Tau expression to preserve vision in glaucoma patients.
https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01804-0

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
